Direct conversion of ustekinumab therapy is more beneficial than infliximab-optimized therapy in patients with Crohn’s disease who develop secondary loss of response to infliximab
Given the high failure rate of IFX optimization, direct conversion to UST may provide greater benefit and reduce treatment costs in patients with CD who develop SLR to IFX.
Authors
- Xiaoping Niu (ORCID: https://orcid.org/0000-0001-8824-0444)
- Li Xie (ORCID: https://orcid.org/0000-0001-7250-4054)
- Jing Wang (ORCID: https://orcid.org/0000-0003-4545-7680)
- Chunlin Li (ORCID: https://orcid.org/0000-0003-3723-5703)
- Xuemei Xu
Institutions
- Wannan Medical College (CN)
- University of Science and Technology of China (CN)
- First Affiliated Hospital of Wannan Medical College (CN)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1186/s12876-025-04319-7
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Anhui University
- University of Science and Technology of China
- Wannan Medical College
- Bijzonder Onderzoeksfonds UGent